Novel Small Molecule Drug Entities Targeting Aminergic G Protein-Coupled Receptors
- Technology Benefits
- The drug entities:ΓÇóAre non-toxic and highly efficientΓÇóAre capable of reversing a variety of disrupted cognitive/behavioral processesΓÇóDo not cause undesirable side effects as observed with conventional therapiesΓÇóHave a unique 5HT2A/2B receptor inverse agonist/antagonist activity together with 5HT2C receptor agonist activity in the same monovalent small moleculeΓÇóDo not have stimulant or sedative properties and are unlikely to be addictive as compared to conventional therapiesΓÇóWould be commercially useful for treatment of various neuropsychiatric, cardiovascular, and metabolic disorders
- Detailed Technology Description
- None
- *Abstract
-
Currently available pharmacotherapies for treating cognitive dysfunctions in neuropsychiatric disorders are inadequate as they are incapable of reversing the associated cognitive disruptions such as inattention, impulsivity, and memory deficit. Moreover, the existing therapies have comparatively low efficacy and are associated with various side effects such as toxicity and weight gain. This invention relates to the development and use of novel drug entities (4-phenyl-1,2,3,4-tetrahydronaphthalen-2-amine (phenylaminotetralin, PAT) analogs) targeting aminergic GPCRs associated with such disorders.
- *Principal Investigator
-
Name: Raymond Both
Department:
- Country/Region
- USA
For more information, please click Here
